The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 2030
Roots Analysis has done a detailed report on Antibody Drug Conjugates Market (5th Edition), 2019-2030.” , covering various important aspects of the industry and identifying key future growth opportunities.


Roots Analysis has done a detailed report on Antibody Drug Conjugates Market (5th Edition), 2019-2030.” , covering various important aspects of the industry and identifying key future growth opportunities.


To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this


Key Market Insights

  • Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
  • Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
  • The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
  • In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
  • A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
  • Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
  • Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
  • The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
  • In the recent years, several developer companies have initiated clinical trials to evaluate the therapeutic potential of ADCs in combination with other drug / therapy classes
  • Anticipating the launch of several product candidates, stakeholders are exploring diverse commercialization strategies across different stages of the launch cycle along with the appropriate reimbursement strategies
  • Given the complexities associated with the development and production of ADCs, CMOs are indispensable to the R&D and manufacturing activity in this domain; some CMOs have even pioneered the novel ADC technology platforms
  • Case Study: In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products
  • With a promising development pipeline and encouraging clinical results, the global market is anticipated to witness growth at an annualized rate of over 20% during the next decade
  • The anticipated future opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized and existing marketing authorizations are expanded


For more information, please visit


Table of Contents



1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines





3.1. Chapter Overview

3.2. Evolution of Anticancer Therapy

3.3. Cancer Treatment Methods

3.3.1. Surgery

3.3.2. Radiation Therapy

3.3.3. Chemotherapy

3.3.4. Targeted Therapies


3.4. Monoclonal Antibody-Based Anticancer Therapies

3.5. Components of Antibody Drug Conjugates (ADCs)

3.5.1. Antibody

3.5.2. Cytotoxin

3.5.3. Linker


3.6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions

3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs

3.8. Pharmacokinetic Properties of ADCs

3.8.1. Absorption

3.8.2. Distribution

3.8.3. Metabolism and Excretion

Gaurav Chaudhary

Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
+1 (415) 800 3415
+44 (122) 391 1091